This retrospective study aimed to investigate outcomes and hospitalization rates in patients with a confirmed diagnosis of early COVID-19 treated at home with prescribed and non-prescribed treatments. MATERIAL AND METHODS: The medical records of a cohort of 158 Italian patients with early COVID-19 treated at home were analyzed. Treatments consisted of indomethacin, low-dose aspirin, omeprazole,… Continue reading Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis of Early COVID-19 and Treated at Home Within 3 Days or After 3 Days of Symptom Onset with Prescribed and Non-Prescribed Treatments Between November 2020 and August 2021
Tag: coronavirus
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
SARS-CoV-2 Omicron (B.1.1.529) variant is highly transmissible with potential immune escape. We conducted a test-negative case-control study to evaluate mRNA-1273 vaccine effectiveness (VE) against infection and hospitalization with Omicron or Delta. The large, diverse study population included 26,683 SARS-CoV-2 test-positive cases with variants determined by S-gene target failure status (16% Delta, 84% Omicron). The 2-dose… Continue reading Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England
BackgroundThromboses in unusual locations after the Coronavirus Disease 2019 (COVID-19) vaccine ChAdOx1-S have been reported, although their frequency with vaccines of different types is uncertain at a population level. The aim of this study was to estimate the population-level risks of hospitalised thrombocytopenia and major arterial and venous thromboses after COVID-19 vaccination. Methods and findingsIn… Continue reading Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England
SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity
Highlights•A previous SARS-CoV-2 infection is associated with a significantly reduced risk of reinfections with efficacy lasting for at least one year and only relatively moderate waning immunity. •Natural immunity shows roughly similar effect sizes regarding protection against reinfection across different SARS-CoV-2 variants, with the exception of the Omicron variant for which data are just emerging… Continue reading SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity
Ipertensione dopo vaccinazione anti-COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread across the world, killing more than 4 million individuals globally, with 240 million individuals being confirmed by laboratory tests. Among different therapeutic strategies to prevent SARS-CoV-2 infection, vaccines are the most promising approach for curbing the pandemic. They elicit an immune neutralizing response and thus offer… Continue reading Ipertensione dopo vaccinazione anti-COVID-19
Quantitative assays reveal cell fusion at minimal levels of SARS-CoV-2 spike protein and fusion from without
Highlights•Minimal levels of SARS-CoV-2 spike protein can cause cell fusion •Spike protein displayed on virus-like particles induces fusion from without •Particle-cell fusion is more sensitive toward neutralization than cell-cell fusion •Highly sensitive and scalable membrane fusion assays are applicable at BSL-1 Cell entry of the pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is mediated… Continue reading Quantitative assays reveal cell fusion at minimal levels of SARS-CoV-2 spike protein and fusion from without
Health-care workers recovered from natural SARS-CoV-2 infection should be exempt frommandatory vaccination edicts
ArticleDownload
Immunocompromised children and young people are at no increased risk of severe COVID-19
Highlights•UK immunocompromised paediatric patients were at no increased risk of severe COVID-19. •Only 4/38 PCR detected infections were admitted to hospital. None had acute severe COVID-19 or died. •Increasing age and immunodeficiency increased reporting of SARS-CoV-2 infection. Worsening of fever, cough and sore throat were associated with reporting SARS-CoV-2 infection. •Serology results suggest there was… Continue reading Immunocompromised children and young people are at no increased risk of severe COVID-19
150 Research Studies Affirm Naturally Acquired Immunity to Covid-19: Documented, Linked, and Quoted
we should not force COVID vaccines on anyone when the evidence shows that naturally acquired immunity is equal to or more robust and superior to existing vaccines. Instead, we should respect the right of the bodily integrity of individuals to decide for themselves. Public health officials and the medical establishment with the help of the… Continue reading 150 Research Studies Affirm Naturally Acquired Immunity to Covid-19: Documented, Linked, and Quoted
2 Medical News 